Skip to main content

Table 1 Clinical characteristics (n = 20)

From: Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis

  Values HR p value
Median age (Yr) 59 (38 – 72) 1.04 0.16
Gender    
M 65% 0.89 0.85
F 35%   
ECOG PS (%)   1.04 0.92
0 30   
1 60   
2 10   
3 & 4 0   
N° of Sites   0.80 0.74
1 75%   
2 25%   
>2 0%   
Initial Sites   0.99 0.99
liver 15%   
lung 10%   
peritoneal 20%   
local 25%   
nodal 0%   
bone 5%   
combinations 25%   
  1. Median age was determined at diagnosis of metastatic disease or at documentation of recurrence. M = male; F = female; ECOG PS Performance Status according to Eastern Cooperative Oncology Group; NO of Sites = number of metastatic sites at diagnosis of metastatic disease or recurrence; Initial Sites = Proportion of initial metastatic/recurrent sites according to the involved organ. HR = Hazard ratio for Overall Survival after univariate analysis. P value = level of significance.